Poly Medicure (NSE:POLYMED) Beneish M-Score: -0.26 (As of Jun. 30, 2026)


NSE:POLYMED Poly Medicure Ltd NSE:POLYMED
90 GF Score
Price ₹1,652.60
GF Value ₹2,289.81
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Poly Medicure Beneish M-Score?

Poly Medicure NSE:POLYMED +0.15% 90 Beneish M-Score is -0.26 as of Jun. 30, 2026. GuruFocus rates NSE:POLYMED with a GF Score™ of 90/100 and a GF Value™ of ₹2,289.81 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Poly Medicure ranks worse than 92.68% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.26 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Poly Medicure's Beneish M-Score or its related term are showing as below:

NSE:POLYMED' s Beneish M-Score Range Over the Past 10 Years
Min: -2.65   Med: -2.32   Max: -0.26
Current: -0.26

During the past 13 years, the highest Beneish M-Score of Poly Medicure was -0.26. The lowest was -2.65. And the median was -2.32.


Poly Medicure Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Poly Medicure's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poly Medicure Beneish M-Score Chart

Poly Medicure Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.17 -2.56 -2.27 -2.24 -0.26

Poly Medicure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.24 0.00 0.00 0.00 -0.26

NSE:POLYMED vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Poly Medicure's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poly Medicure Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Poly Medicure's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Poly Medicure's Beneish M-Score falls into.


NSE:POLYMED
90GF Score
Poly Medicure Ltd NSE:POLYMED
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Poly Medicure Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Poly Medicure for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3165+0.528 * 0.9789+0.404 * 5.2253+0.892 * 1.123+0.115 * 0.8386
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.021671-0.327 * 1.3898
=-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹5,319 Mil.
Revenue was ₹18,753 Mil.
Gross Profit was ₹12,784 Mil.
Total Current Assets was ₹19,417 Mil.
Total Assets was ₹39,186 Mil.
Property, Plant and Equipment(Net PPE) was ₹13,536 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,155 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹5,755 Mil.
Long-Term Debt & Capital Lease Obligation was ₹572 Mil.
Net Income was ₹3,313 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹2,464 Mil.
Total Receivables was ₹3,598 Mil.
Revenue was ₹16,698 Mil.
Gross Profit was ₹11,144 Mil.
Total Current Assets was ₹19,170 Mil.
Total Assets was ₹31,925 Mil.
Property, Plant and Equipment(Net PPE) was ₹11,783 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹832 Mil.
Selling, General, & Admin. Expense(SGA) was ₹653 Mil.
Total Current Liabilities was ₹3,702 Mil.
Long-Term Debt & Capital Lease Obligation was ₹8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5319.17 / 18752.592) / (3597.679 / 16698.316)
=0.28365 / 0.215452
=1.3165

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(11143.889 / 16698.316) / (12784.48 / 18752.592)
=0.667366 / 0.681745
=0.9789

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (19417.332 + 13536.211) / 39185.672) / (1 - (19169.971 + 11782.867) / 31924.522)
=0.159041 / 0.030437
=5.2253

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=18752.592 / 16698.316
=1.123

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(831.822 / (831.822 + 11782.867)) / (1155.166 / (1155.166 + 13536.211))
=0.065941 / 0.078629
=0.8386

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 18752.592) / (652.88 / 16698.316)
=0 / 0.039099
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((572.488 + 5755.224) / 39185.672) / ((7.713 + 3701.692) / 31924.522)
=0.16148 / 0.116193
=1.3898

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3312.921 - 0 - 2463.746) / 39185.672
=0.021671

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Poly Medicure has a M-score of -0.26 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.26 mean?
Poly Medicure (NSE:POLYMED) has a Beneish M-Score of -0.26 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Poly Medicure and its competitors. According to the industry distribution chart, Poly Medicure ranks #709 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 92.7%.
Is Poly Medicure's Beneish M-Score too high?
Poly Medicure's current Beneish M-Score is -0.26. Based on the distribution chart, Poly Medicure ranks #709 out of 765 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Poly Medicure has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Poly Medicure's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Poly Medicure ranks #709 out of 765 companies for Beneish M-Score. This places Poly Medicure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Poly Medicure and its competitors. Poly Medicure's current Beneish M-Score is -0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poly Medicure stock overvalued right now?
Based on GuruFocus' analysis, Poly Medicure (NSE:POLYMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,289.81, compared to a current price of ₹1,652.60 — trading 27.8% below its estimated fair value. The current Beneish M-Score is -0.26. Poly Medicure's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Poly Medicure (NSE:POLYMED), the current Beneish M-Score is -0.26 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poly Medicure (NSE:POLYMED) Overvalued in 2026?

Based on GuruFocus' analysis, Poly Medicure stock appears to be undervalued. The current stock price of ₹1,652.60 is trading 27.8% below its estimated GF Value™ of ₹2,289.81. GuruFocus considers Poly Medicure to be Modestly Undervalued.

Key valuation signals for NSE:POLYMED:

  • Beneish M-Score: -0.26
  • GF Value™: ₹2,289.81 vs. price of ₹1,652.60 (27.8% below fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the NSE:POLYMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Poly Medicure Business Description

Other Exchanges 531768:India
Address Okhla Industrial Estate, 232-B, 3rd Floor, Phase III, New Delhi, IND, 110020
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
90GF Score

Get the complete analysis for NSE:POLYMED

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,652.60
Price
₹2,289.81
GF Value